The abstract is read at the publisher; the summary is JClub's.
In the AnswerALS cohort, ALS patients with the highest G1 or G2-phase cyclin expression show significantly slower ALSFRS-R decline, while S-phase marker engagement correlates with faster progression.
- Why it matters: ALS clinical heterogeneity limits therapy, and it is unclear whether neuronal cell-cycle re-entry meaningfully stratifies patient outcomes rather than simply reflecting neurodegeneration.
- What they did: The study integrates AnswerALS large-scale transcriptomics with mechanistic experiments in human iPSC-derived spinal motor neurons, linking nucleocytoplasmic transport dysfunction to cell-cycle reactivation and TDP-43 pathology.
- The result: Impaired nuclear import initiates TDP-43 pathology and mis-localization, triggers a transient cell-cycle wave before neuronal death, and CDK4/6 inhibition prevents S-phase entry and confers neuroprotection.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.